Ireland
--:--IST
Latest
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Recommended or optimised

836 appraisals, newest first, page 9 of 9
AppraisalMedicine pageNICE recommendationPublishedStatus
The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy
NICE TA41
—Recommended27 May 2002Replaced by TA156
The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease
NICE TA40
InfliximabRecommended26 Apr 2002Current
The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation
NICE TA39
Nicotine replacement, BupropionRecommended27 Mar 2002Current
Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years)
NICE TA38
—Recommended27 Mar 2002Current
The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis
NICE TA36
EtanerceptOptimised27 Mar 2002Replaced by TA130
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis
NICE TA35
EtanerceptRecommended27 Mar 2002Current
Guidance on the use of trastuzumab for the treatment of advanced breast cancer
NICE TA34
TrastuzumabRecommended15 Mar 2002Current
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
NICE TA33
Irinotecan, Oxaliplatin, RaltitrexedNot recommended Recommended Optimised Only in research27 Mar 2002Replaced by TA93
The clinical effectiveness and cost effectiveness of sibutramine for obesity
NICE TA31
—Recommended28 Oct 2001Replaced
Taxanes for the treatment of breast cancer
NICE TA30
Docetaxel, PaclitaxelNot recommended Recommended26 Sep 2001Replaced
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
NICE TA29
FludarabineRecommended26 Sep 2001Current
Ovarian cancer - topotecan
NICE TA28
TopotecanRecommended23 Jul 2001Replaced by TA91
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
NICE TA27
CelecoxibOptimised23 Jul 2001Replaced
Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer
NICE TA26
Docetaxel, Gemcitabine, Paclitaxel, VinorelbineRecommended26 Jun 2001Replaced
Guidance on the use of gemcitabine for the treatment of pancreatic cancer
NICE TA25
GemcitabineRecommended Not recommended8 May 2001Replaced
Wound care - debriding agents
NICE TA24
—Recommended27 Apr 2001Replaced
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
NICE TA23
TemozolomideRecommended26 Apr 2001
Updated 3 Mar 2016
Current
Orlistat for the treatment of obesity in adults
NICE TA22
OrlistatRecommended27 Mar 2001Replaced
Diabetes (type 2) - pioglitazone
NICE TA21
PioglitazoneRecommended27 Mar 2001Replaced by TA63
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease
NICE TA20
RiluzoleRecommended23 Jan 2001Current
Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine
NICE TA19
Donepezil, GalantamineOptimised23 Jan 2001Replaced by TA111
Laparoscopic surgery for hernia
NICE TA18
—Recommended23 Jan 2001Replaced by TA83
Zanamivir for the treatment of influenza in adults
NICE TA15
—Recommended27 Nov 2000Replaced by TA58
The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C
NICE TA14
—Recommended28 Oct 2000Replaced by TA75
Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents
NICE TA13
MethylphenidateRecommended28 Oct 2000Replaced
Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
NICE TA12
TirofibanRecommended26 Sep 2000Replaced by TA47
Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias
NICE TA11
—Recommended26 Sep 2000Replaced by TA95
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
NICE TA10
—Recommended23 Aug 2000Current
Diabetes (type 2) - rosiglitazone
NICE TA9
—Recommended23 Aug 2000Replaced by TA63
Hearing disability - hearing aids
NICE TA8
—Not recommended Recommended23 Jul 2000Withdrawn
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia
NICE TA7
Lansoprazole, Omeprazole, Pantoprazole, RabeprazoleRecommended23 Jul 2000Replaced
Taxanes for the treatment of breast cancer
NICE TA6
Docetaxel, PaclitaxelRecommended26 Jun 2000Replaced by TA30
Ischaemic heart disease - coronary artery stents
NICE TA4
—Recommended27 May 2000Replaced by TA71
Ovarian cancer - taxanes
NICE TA3
PaclitaxelRecommended27 May 2000Replaced by TA55
Guidance on the Selection of Prostheses for Primary Total Hip Replacement
NICE TA2
—Recommended26 Apr 2000Replaced by TA304
Guidance on the extraction of wisdom teeth
NICE TA1
—Recommended27 Mar 2000Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.